TY - JOUR
T1 - Incidence of mental health hospitalizations, treated self-harm, and emergency room visits following new anxiety disorder diagnoses in privately insured U.S. children
AU - Bushnell, Greta A.
AU - Gaynes, Bradley N.
AU - Compton, Scott N.
AU - Dusetzina, Stacie B.
AU - Brookhart, M. Alan
AU - Stürmer, Til
N1 - Funding Information:
Dr. Brookhart has received investigator-initiated research funding from the NIH and through contracts with the AHRQ's DEcIDE program and the PCORI. Within the past three years, he has received research support from Amgen and AstraZeneca and has served as a scientific advisor for Amgen, Merck, GSK, Genentech, TargetPharma, and RxAnte. Dr. Brookhart owns equity in NoviSci, LLC, a data sciences company.
Funding Information:
Dr. Bushnell receives support from the National Institute of Mental Health, previously as a Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellow (F31MH107085), and currently under award number T32MH013043. She previously held a graduate research assistantship with GlaxoSmithKline and was the Merck fellow for the Center for Pharmacoepidemiology (both ended 12/2015).
Funding Information:
informationNational Institute of Mental Health, Grant/Award Number: F31MH107085Research reported in this publication was supported by the National Institute of Mental Health (Bethesda, MD) under Award Number F31MH107085 (G. Bushnell). This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The database infrastructure was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health, the Cecil G. Sheps Center for Health Services Research, UNC, the CER Strategic Initiative of UNC's Clinical Translational Science Award (UL1TR002489), and the UNC School of Medicine (Chapel Hill, NC). The funding source had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Funding Information:
Dr. Compton receives research support from the National Institute of Mental Health, NC GlaxoSmithKline Foundation, Mursion, Inc. and has been a consultant for Shire, received honoraria from the Journal of Consulting and Clinical Psychology, Nordic Long-Term OCD Treatment Study Research Group, and The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway, and given expert testimony for Duke University.
Funding Information:
Research reported in this publication was supported by the National Institute of Mental Health (Bethesda, MD) under Award Number F31MH107085 (G. Bushnell). This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The database infrastructure was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health, the Cecil G. Sheps Center for Health Services Research, UNC, the CER Strategic Initiative of UNC's Clinical Translational Science Award (UL1TR002489), and the UNC School of Medicine (Chapel Hill, NC). The funding source had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Funding Information:
Dr. Stürmer receives investigator-initiated research funding from the National Institutes of Health (Principal Investigator, R01 AG056479; Co-Investigator: R01 CA174453, R01 HL118255, R21-HD080214). He also receives salary support as Director of the Comparative Effectiveness Research Strategic Initiative, NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR002489) the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Merck, Shire) and research support from pharmaceutical companies (Amgen, AstraZeneca, Novo Nordisk) to the Department of Epidemiology, University of North Carolina at Chapel Hill. Dr. Stürmer does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, BASF, AstraZeneca, and Novo Nordisk.
Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2019/2
Y1 - 2019/2
N2 - Background: Anxiety disorders are one of the most common mental illnesses in children and associated with high healthcare utilization. We aimed to estimate 2-year cumulative incidence of mental health–related hospitalizations, treated self-harm, and emergency room (ER) visits in children newly diagnosed with anxiety disorders and, for context, in children without anxiety disorders. Methods: We identified commercially insured treatment naïve children (3–17 years) with a new office-based anxiety disorder diagnosis (ICD-9-CM) from 2005–2014 in the MarketScan claims database. We followed children for up to 2 years after diagnosis for the first of each event: mental health–related hospitalization, inpatient, treated self-harm, and ER visits (any, anxiety-related, injury-related). Children without anxiety diagnoses were included as comparators, matched on age, sex, date, and region. We estimated cumulative incidence of each event using Kaplan–Meier analysis. Results: From 2005–2014, we identified 198,450 children with a new anxiety diagnosis. One-year after anxiety diagnosis, 2.0% of children had a mental health–related hospitalization, 0.08% inpatient, treated self-harm, 1.4% anxiety-related ER visit, and 20% any ER visit; incidence was highest in older children with baseline comorbid depression. One-year cumulative incidence of each event was lower in the comparison cohort without anxiety (e.g., mental health–related hospitalizations = 0.5%, treated self-harm = 0.01%, and ER visits = 13%). Conclusions: Given the prevalence of anxiety disorders, 2-year incidence estimates translate to a significant number of children experiencing each event. Our findings offer caregivers, providers, and patients information to better understand the burden of anxiety disorders and can help anticipate healthcare utilization and inform efforts to prevent these serious events.
AB - Background: Anxiety disorders are one of the most common mental illnesses in children and associated with high healthcare utilization. We aimed to estimate 2-year cumulative incidence of mental health–related hospitalizations, treated self-harm, and emergency room (ER) visits in children newly diagnosed with anxiety disorders and, for context, in children without anxiety disorders. Methods: We identified commercially insured treatment naïve children (3–17 years) with a new office-based anxiety disorder diagnosis (ICD-9-CM) from 2005–2014 in the MarketScan claims database. We followed children for up to 2 years after diagnosis for the first of each event: mental health–related hospitalization, inpatient, treated self-harm, and ER visits (any, anxiety-related, injury-related). Children without anxiety diagnoses were included as comparators, matched on age, sex, date, and region. We estimated cumulative incidence of each event using Kaplan–Meier analysis. Results: From 2005–2014, we identified 198,450 children with a new anxiety diagnosis. One-year after anxiety diagnosis, 2.0% of children had a mental health–related hospitalization, 0.08% inpatient, treated self-harm, 1.4% anxiety-related ER visit, and 20% any ER visit; incidence was highest in older children with baseline comorbid depression. One-year cumulative incidence of each event was lower in the comparison cohort without anxiety (e.g., mental health–related hospitalizations = 0.5%, treated self-harm = 0.01%, and ER visits = 13%). Conclusions: Given the prevalence of anxiety disorders, 2-year incidence estimates translate to a significant number of children experiencing each event. Our findings offer caregivers, providers, and patients information to better understand the burden of anxiety disorders and can help anticipate healthcare utilization and inform efforts to prevent these serious events.
KW - anxiety disorders
KW - child
KW - emergency service
KW - healthcare utilization
KW - hospitalization
KW - incidence
KW - self-injurious behavior
UR - http://www.scopus.com/inward/record.url?scp=85055491934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055491934&partnerID=8YFLogxK
U2 - 10.1002/da.22849
DO - 10.1002/da.22849
M3 - Article
C2 - 30358025
AN - SCOPUS:85055491934
SN - 1091-4269
VL - 36
SP - 179
EP - 189
JO - Depression and Anxiety
JF - Depression and Anxiety
IS - 2
ER -